Compare Stocks: KLRA, APGE, TGTX, and IBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.34	1.26 million shs	948,283 shs
IBRX ImmunityBio	$7.79 -0.6%	$7.78	$1.95 ▼ $12.43	$8.26B	0.03	8.87 million shs	7.59 million shs
KLRA Kailera Therapeutics	$17.17 -1.7%	$19.28	$16.39 ▼ $28.23	$2.23B	N/A	545,586 shs	436,829 shs
TGTX TG Therapeutics	$54.27 +7.3%	$53.02	$26.76 ▼ $59.30	$8.31B	1.62	2.21 million shs	5.55 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.15%	+0.36%	+66.03%	+274.10%
IBRX ImmunityBio	0.00%	+2.91%	+5.27%	+7.89%	+244.69%
KLRA Kailera Therapeutics	0.00%	-4.29%	-1.32%	-18.89%	+1,716,999,900.00%
TGTX TG Therapeutics	0.00%	+11.35%	-2.22%	+39.62%	+91.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.34	1.26 million shs	948,283 shs
IBRX ImmunityBio	$7.79 -0.6%	$7.78	$1.95 ▼ $12.43	$8.26B	0.03	8.87 million shs	7.59 million shs
KLRA Kailera Therapeutics	$17.17 -1.7%	$19.28	$16.39 ▼ $28.23	$2.23B	N/A	545,586 shs	436,829 shs
TGTX TG Therapeutics	$54.27 +7.3%	$53.02	$26.76 ▼ $59.30	$8.31B	1.62	2.21 million shs	5.55 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.15%	+0.36%	+66.03%	+274.10%
IBRX ImmunityBio	0.00%	+2.91%	+5.27%	+7.89%	+244.69%
KLRA Kailera Therapeutics	0.00%	-4.29%	-1.32%	-18.89%	+1,716,999,900.00%
TGTX TG Therapeutics	0.00%	+11.35%	-2.22%	+39.62%	+91.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.20	Hold	$124.43	-7.66% Downside
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	82.28% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	148.98% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	16.09% Upside

Current Analyst Ratings Breakdown

Latest KLRA, APGE, TGTX, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/4/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
7/29/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
7/27/2026	TGTX TG Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $86.00
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $77.00
7/10/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	TGTX TG Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underperform	$17.00 ➝ $20.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
IBRX ImmunityBio	$113.29M	72.88	N/A	N/A	($0.99) per share	-7.87
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	$8.63 per share	N/A
TGTX TG Therapeutics	$616.29M	13.48	$2.80 per share	19.37	$3.95 per share	13.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	$447.18M	$2.74	19.81	20.48	2.33	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest KLRA, APGE, TGTX, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million
5/26/2026	Q1 2026	KLRA Kailera Therapeutics	N/A	-$3,650.00	N/A	-$3,650.00	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
IBRX ImmunityBio	N/A	5.72	5.70
KLRA Kailera Therapeutics	N/A	11.11	11.11
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
IBRX ImmunityBio	8.58%
KLRA Kailera Therapeutics	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
IBRX ImmunityBio	66.10%
KLRA Kailera Therapeutics	N/A
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

KLRA, APGE, TGTX, and IBRX Headlines

Recent News About These Companies

Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX

August 23 at 5:19 AM | marketbeat.com

235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG

August 23 at 3:36 AM | marketbeat.com

Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

August 23 at 1:20 AM | americanbankingnews.com

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

August 22 at 10:00 AM | seekingalpha.com

BlackRock Inc. Takes Position in TG Therapeutics, Inc. $TGTX

August 22 at 3:21 AM | marketbeat.com

TGTX stock alert: What to know as takeover rumors swirl around TG Therapeutics

August 21 at 11:49 PM | msn.com

TG Therapeutics (NASDAQ:TGTX) Trading 10.1% Higher - Should You Buy?

August 21 at 12:19 PM | marketbeat.com

TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

August 21 at 10:59 AM | marketbeat.com

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

August 17, 2026 | marketbeat.com

Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Hold" from Analysts

August 13, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP

August 10, 2026 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages

August 8, 2026 | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

August 7, 2026 | marketbeat.com

California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX

August 6, 2026 | marketbeat.com

HC Wainwright Expects Higher Earnings for TG Therapeutics

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co.

August 5, 2026 | marketbeat.com

Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Stock Holdings Boosted by Dimensional Fund Advisors LP

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA, APGE, TGTX, and IBRX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$134.75 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

ImmunityBio NASDAQ:IBRX

$7.79 -0.05 (-0.64%)

As of 08/21/2026 04:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Kailera Therapeutics NASDAQ:KLRA

$17.17 -0.29 (-1.66%)

As of 08/21/2026 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$54.27 +3.71 (+7.34%)

As of 08/21/2026 04:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KLRA, APGE, TGTX, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KLRA, APGE, TGTX, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KLRA, APGE, TGTX, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA, APGE, TGTX, and IBRX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

ImmunityBio NASDAQ:IBRX

Kailera Therapeutics NASDAQ:KLRA

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KLRA, APGE, TGTX, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KLRA, APGE, TGTX, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KLRA, APGE, TGTX, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA, APGE, TGTX, and IBRX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

ImmunityBio NASDAQ:IBRX

Kailera Therapeutics NASDAQ:KLRA

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools